Market Place
Sourcing Support
Iovance Submits Marketing Application To EMA For Lifileucel In Advanced Melanoma
28 Jun 2024 //
GLOBENEWSWIRE
BMS` triplet, Iovance`s Amtagvi-Keytruda target melanoma
24 May 2024 //
FIERCE PHARMA
Iovance Biotherapeutics Q1 2024 Financials And Corporate Update
09 May 2024 //
GLOBENEWSWIRE
US FDA grants accelerated approval for Iovance`s skin cancer cell therapy
17 Feb 2024 //
REUTERS
Iovance Biotherapeutics Announces Clinical Data for Lifileucel at ESMO
16 Oct 2023 //
GLOBENEWSWIRE
U.S. Food and Drug Administration Updates PDUFA Action Date for Lifileucel
14 Sep 2023 //
GLOBENEWSWIRE
Iovance Provides Update on BLA Submission for Lifileucel in Advanced Melanoma
18 Nov 2022 //
GLOBENEWSWIRE
Iovance hammered as cell therapy disappoints
27 May 2022 //
EVALUATE
Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel
26 May 2022 //
GLOBENEWSWIRE
Iovance Bio Announces Regulatory and Clinical Updates for Lifileucel in Melanoma
05 Apr 2022 //
GLOBENEWSWIRE
Iovance Reports Pivotal Cohort 4 Data for (TIL) Therapy Lifileucel C-144-01
27 May 2020 //
GLOBENEWSWIRE
Iovance comes back with another upbeat cancer trial update
01 Jun 2019 //
ENDPTS
Iovance Biotherapeutics Expands Partnership with WuXi
30 May 2019 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.